[1]孙晓华,宋雨霖,李 红.子宫内膜异位症患者血清VEGFR-1 和MIP-3α 水平表达对术后复发的预测价值研究[J].现代检验医学杂志,2024,39(04):170-174.[doi:10.3969/j.issn.1671-7414.2024.04.031]
　SUN Xiaohua,SONG Yulin,LI Hong.Study on the Predictive Value of Serum VEGFR-1 and MIP-3α Level Expression in Endometriosis Patients on Postoperative Recurrence[J].Journal of Modern Laboratory Medicine,2024,39(04):170-174.[doi:10.3969/j.issn.1671-7414.2024.04.031]
点击复制

子宫内膜异位症患者血清VEGFR-1 和MIP-3α 水平表达对术后复发的预测价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
170-174
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Study on the Predictive Value of Serum VEGFR-1 and MIP-3α Level Expression in Endometriosis Patients on Postoperative Recurrence
文章编号:
1671-7414（2024）04-170-05
作者:
孙晓华; 宋雨霖; 李 红
（秦皇岛市妇幼保健院，河北秦皇岛 066000）
Author(s):
SUN Xiaohua; SONG Yulin; LI Hong
（Maternal and Child Care Hospital of Qinhuangdao, Hebei Qinhuangdao 066000，China）
关键词:
血管内皮生长因子受体1; 巨噬细胞炎性蛋白-3α; 子宫内膜异位症
分类号:
R711.71；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.04.031
文献标志码:
A
摘要:
目的 探究血清血管内皮生长因子受体1（vascular endothelial growth factor receptor-1，VEGFR-1）和巨噬细胞炎性蛋白-3α（macrophage inflammatory protein-3α，MIP-3α）在子宫内膜异位症（endometriosis，EMs）患者中的表达以及两者联合检测对EMs 患者术后复发的预测价值。方法 选取2019 年4 月～ 2021 年6 月秦皇岛市妇幼保健院行腹腔镜手术治疗的114 例EMs 患者作为观察组，同期选择在该院体检的孕龄期女性114 例健康体检者作为对照组。采用酶联免疫吸附法（ELISA）测定患者血清中VEGFR-1 和MIP-3α 水平；根据术后二年复发情况，将其分为复发组（n=78）和未复发组（n=36）。采用多因素Logistic 回归分析EMs 患者术后复发的影响因素；采用受试者工作特征（receiver operating characteristic，ROC）曲线分析血清VEGFR-1 与MIP-3α 联合检测对EMs 患者术后复发的预测价值。结果 与对照组相比，观察组VEGFR-1（116.25±48.57pg/ml vs 92.43±25.37pg/ml）及MIP-3α（19.25±5.24pg/ml vs 13.67±4.28pg/ml）水平升高，差异具有统计学意义（t=4.641，8.806，均P ＜ 0.05）。轻度、中度、重度EMs 患者VEGFR-1 水平（104.22±5.78pg/ml，118.60±6.56pg/ml，138.55±7.85pg/ml）和MIP-3α 水平（15.37±1.15pg/ml，19.28±2.12pg/ml，25.42±2.56pg/ml）依次升高，差异具有统计学意义（F=147.757，133.654，均P ＜ 0.001）。复发组中后穹隆存在触痛结节及r-AFS 分期（Ⅲ～Ⅳ期）占比显著大于未复发组（χ2=15.139，10.310，均P ＜ 0.05）；复发组术后用药6 个月及以上占比显著低于未复发组（χ2=15.016，P ＜ 0.001），差异具有统计学意义。多因素Logistic回归分析显示，血清VEGFR-1，MIP-3α，后穹隆存在触痛结节及r-AFS 分期为EMs 术后复发的危险因素（均P＜ 0.05），术后用药6 个月及以上为保护因素（P ＜ 0.05）。ROC 曲线显示，血清VEGFR-1 与MIP-3α 联合预测EMs术后复发的曲线下面积（area under the curve，AUC）最大（0.929），其敏感度和特异度分别为85.90% 和86.11%。结论 VEGFR-1 及MIP-3α 在EMs 患者血清中表达升高，且二者联合检测在预测EMs 术后复发的效能更佳。
Abstract:
Objective To investigate the expression of serum vascular endothelial growth factor receptor-1 (VEGFR-1) and macrophage inflammatory protein-3α (MIP-3α) in patients with endometriosis (EMs) patients and the predictive value of their combined detection for postoperative recurrence in EMs patients. Methods A total of 114 patients with EMs who underwent laparoscopic surgery in Maternal and Child Care Hospital of Qinhuangdao from April 2019 to June 2021 were selected as the observation group, while 114 healthy medical checkups of women of gestational age who had their medical checkups in the hospital were selected as the control group during the same period. Enzyme-linked immunosorbent assay (ELISA) was used to determine the serum levels of VEGFR-1 and MIP-3α in the patients. According to the postoperative period of 2 years, they were divided into the recurrence group (n=78) and the non-recurrence group (n=36). Multivariate logistic regression analysis was used to analyze influencing factors of postoperative recurrence in patients with EMs. The predictive value of the combined serum VEGFR-1 and MIP-3α test for postoperative recurrence in patients with EMs was analyzed by using the receiver operating characteristic curve (ROC) curve. Results Compared with the control group, the levels of VEGFR-1 in the observation group (116.25 ± 48.57 pg/ml vs 92.43 ± 25.37 pg/ml) and MIP-3α (19.25 ± 5.24 pg/ml vs 13.67 ± 4.28 pg/ml) were elevated, and the differences were significant (t = 4.641, 8.806, all P<0.05). The level of VEGFR-1 (104.22 ± 5.78 pg/ml, 118.60 ± 6.56 pg/ml, 138.55 ± 7.85 pg/ml）and the level of MIP-3α（15.37 ± 1.15 pg/ml, 19.28 ± 2.12 pg/ml, 25.42 ± 2.56 pg/ml) in mild, moderate and severe EMs patients were increased successively，and the differences were significant (F=147.757, 133.654, all P < 0.001). The percentage of the presence of palpable nodules in the posterior fornix ，r-AFS staging (stage III ～ IV) in the recurrence group was greater than those in the non-recurrence group (χ2 = 15.139, 10.310, all P < 0.05), and the percentage of the recurrence group with postoperative medication for 6 months or more was lower than that of the non-recurrence group (χ2 = 15.016, P < 0.001), and the differences were statistically significant, respectively. Multivariate logistic regression analysis showed that serum VEGFR-1, MIP-3α, the presence of palpable nodules in the posterior fornix and r-AFS staging were risk factors for postoperative recurrence of EMs (all P< 0.05), while postoperative medication for 6 months or more was a protective factor (P < 0.05). The ROC curves showed that the area under the curve (AUC) of the combination of serum VEGFR-1 and MIP-3α predicted postoperative EMs for postoperative recurrence was the largest (0.929), and its sensitivity and specificity were 85.90% and 86.11%, respectively. Conclusion VEGFR-1 and MIP-3α expression was elevated in the serum of patients with EMs. The efficacy of their combined detection in predicting recurrence after EMs could be better.

参考文献/References:

[1] 杨珈苹, 苏翠滢, 贾英. 子宫内膜异位症相关性卵巢癌的临床特征及预后分析[J]. 重庆医学, 2023,52(7): 1015-1020. YANG Jiaping, SU Cuiying, JIA Ying. Clinical characteristics and prognosis of endometriosisassociated ovarian cancer [J]. Chongqing Medicine, 2023, 52(7): 1015-1020.
[2] 张琦, 周锋, 李岚, 等. 子宫内膜异位症患者腹腔镜手术后首次IVF-ET 的治疗结局分析[J]. 中华妇产科杂志, 2023, 58(2): 91-97. ZHANG Qi, ZHOU Feng, LI Lan, et al. Analysis of reproductive outcomes in the first IVF-ET cycle after laparoscopic treatment in patients with endometriosis [J]. Chinese Journal of Obstetrics and Gynecology, 2023, 58(2): 91-97.
[3] 郁平, 姬小凡, 王敏, 等. 腹腔镜手术联合亮丙瑞林、戊酸雌二醇治疗子宫内膜异位症效果及对腹腔液血管内皮生长因子、糖类抗原125 水平影响[J]. 临床误诊误治, 2020, 33(2): 46-51. YU Ping, JI Xiaofan, WANG Min, et al. Effects of laparoscopic surgery combined with leuprolide and estradiol valerate on endometriosis and its influence on vascular endothelial growth factor and carbohydrate antigen 125 in peritoneal fluid[J]. Clinical Misdiagnosis & Mistherapy, 2020, 33(2): 46-51.
[4] HATTORI K, ITO Y, HONDA M, et al. Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice[J]. Journal of Pharmacological Sciences, 2020, 143(4): 255-263.
[5] 卢莺燕, 辛娇娇, 丁文超, 等. 巨噬细胞炎性蛋白-3α 在乙型肝炎相关慢加急性肝衰竭患者中的表达及其诊断价值[J]. 中华肝脏病杂志, 2021, 29(12):1156-1163. LU Yingyan, XIN Jiaojiao, DING Wenchao, et al. Expression and diagnostic value of macrophage inflammatory protein-3α in patients with hepatitis B-related acute-on-chronic live failure[J]. Chinese Journal of Hepatology, 2021, 29(12): 1156-1163.
[6] LEE D Y, KIM S K, LEE J R, et al. Management of endometriosis-related infertility: Considerations and treatment options[J]. Clinical and Experimental Reproductive Medicine, 2020, 47(1): 1-11.
[7] 中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J]. 中华妇产科杂志,2015, 56(3): 161-169. Cooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guideline for the diagnosis and treatment of endometriosis [J]. Chinese Journal of Obstetrics and Gynecology, 2015, 56(3): 161-169.
[8] 陈霄, 吴小颖, 安明. 血清CXC 趋化因子配体14和肿瘤坏死因子超家族成员13 水平对卵巢子宫内膜异位症患者术后复发的预测价值[J]. 中国医药,2023, 18(9): 1366-1370. CHEN Xiao, WU Xiaoying, AN Ming. Predictive value of serum CXC chemokine ligand 14 and tumor necrosis factor superfamily member 13 in postoperative recurrence in patients with ovarian endometriosis [J]. China Medicine, 2023, 18(9): 1366-1370.
[9] 张璇, 赵爱琴, 邹丹, 等. 子宫内膜异位症患者血清miR-455 和FABP4 表达水平及临床意义[J]. 现代检验医学杂志, 2022, 37(4): 49-52, 158. ZHANG Xuan, ZHAO Aiqin, ZOU Dan, et al. Expression level and clinical significance of serum miR-455 and FABP4 in patients with endometriosis [J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 49-52, 158.
[10] 曾辉苑, 张燕, 刘国栋, 等. 子宫内膜异位症患者血清中PAPP-A,IGF-I 水平及PAPP-A 基因rs7020782A/C 位点多态性与临床分期相关性研究[J]. 现代检验医学杂志, 2022, 37(1): 33-37. ZENG Huiyuan, ZHANG Yan, LIU Guodong, et al. Study on the correlation between the levels of PAPP-A,IGF-I and PAPP-A gene rs7020782 A/C loci polymorphism and clinical stage in patients with endometriosis [J]. Journal of Modern Laboratory Medicine, 2022, 37(1): 33-37.
[11] CECI C, ATZORI M G, LACAL P M, et al. Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models[J]. International Journal of Molecular Sciences, 2020, 21(4): 1388.
[12] TANG Ting, LAI Huichao, HUANG Xuemei, et al. Application of serum markers in diagnosis and staging of ovarian endometriosis[J]. Journal of Obstetrics and Gynaecology Research, 2021, 47(4): 1441-1450.
[13] SEKIGUCHI K, ITO Y, HATTORI K, et al. VEGF receptor 1-Expressing macrophages recruited from bone marrow enhances angiogenesis in endometrial tissues[J]. Scientific Reports, 2019, 9(1): 7037.
[14] 袁洁玲. 趋化因子MIP-1α 及其受体CCR5 在子宫内膜异位症中表达的探究[D]. 太原：山西医科大学,2020. YUAN Jieling. Study on exploration of chemokine MIP-1α and its receptor CCR5 in endometriosis[D]. Taiyuan：Shanxi Medical University, 2020.
[15] HUANG Fengying, WANG Jinyan, DAI Shuzhen, et al. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity[J]. Journal for Immunotherapy of Cancer, 2020, 8(2): e000330.
[16] NOWAK M, JANAS ?, SOJA M, et al. Chemokine expression in patients with ovarian cancer or benign ovarian tumors[J]. Archives of Medical Science, 2022, 18(3): 682-689.
[17] UDAYASURYAN B, AHMAD R N, NGUYEN T, et al. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling[J]. Science Signaling, 2022, 15(756): eabn4948.
[18] JAB?O?SKI G, SOBKIEWICZ B, KACZMAREK M, et al. Serum concentrations of CCL20/MIP-3alpha in women with endometriosis[J]. Przeglad Menopauzalny, 2019, 18(1): 9-14.
[19] ZHONG Qiyu, YANG Fan, CHEN Xiaochuan, et al. Patterns of immune infiltration in endometriosis and their relationship to r-AFS stages[J]. Frontiers in Genetics, 2021, 12: 631715.
[20] BINDRA V, REDDY N, REDDY C A, et al. Recurrent perineal scar endometriosis: a case report[J]. Case Reports in Women’s Health, 2022, 36: e00457.

备注/Memo

备注/Memo:
基金项目：秦皇岛市科学技术研究与发展计划任务书（编号：202301A214）。
作者简介：孙晓华（1981-），女，硕士研究生，副主任医师，研究方向：妇科肿瘤，E-mail：f75tni@163.com。
更新日期/Last Update: 2024-07-15